Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Am J Cardiovasc Drugs. 2012 Feb 1;12(1):49-56. doi: 10.2165/11209150-000000000-00000.
Ezetimibe/simvastatin therapy combines two lipid-lowering compounds with complementary mechanisms of action, thereby blocking the two sources of plasma cholesterol and improving lipid profiles. Ezetimibe/simvastatin is an effective and generally well tolerated adjunct to dietary therapy for markedly reducing low-density lipoprotein cholesterol (LDL-C) levels and improving other lipid parameters across diverse patient populations. Dual treatment with ezetimibe/simvastatin is more effective than monotherapy with an HMG-CoA reductase inhibitor (statin), and the addition of ezetimibe to current statin therapy is more effective than doubling the statin dose.
依折麦布/辛伐他汀治疗方案结合了两种降脂化合物,它们具有互补的作用机制,从而阻断了血浆胆固醇的两个来源,并改善了血脂谱。依折麦布/辛伐他汀是一种有效的、通常耐受性良好的辅助药物,可用于饮食治疗,显著降低低密度脂蛋白胆固醇(LDL-C)水平,并改善各种患者群体的其他脂质参数。依折麦布/辛伐他汀联合治疗比单独使用 HMG-CoA 还原酶抑制剂(他汀类药物)更有效,而且依折麦布联合当前的他汀类药物治疗比加倍他汀类药物剂量更有效。